1.50
+0.01(+0.67%)
Currency In USD
| Previous Close | 1.49 |
| Open | 1.5 |
| Day High | 1.56 |
| Day Low | 1.48 |
| 52-Week High | 12.45 |
| 52-Week Low | 1.22 |
| Volume | 173,461 |
| Average Volume | 159,403 |
| Market Cap | 4.84M |
| PE | 21.43 |
| EPS | 0.07 |
| Moving Average 50 Days | 1.42 |
| Moving Average 200 Days | 2.32 |
| Change | 0.01 |
If you invested $1000 in 60 Degrees Pharmaceuticals, Inc. (SXTP) since IPO date, it would be worth $5.34 as of October 20, 2025 at a share price of $1.5. Whereas If you bought $1000 worth of 60 Degrees Pharmaceuticals, Inc. (SXTP) shares 1 year ago, it would be worth $280.37 as of October 20, 2025 at a share price of $1.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
GlobeNewswire Inc.
Oct 15, 2025 11:14 AM GMT
Breakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA)Results obtained using highest sensitivity test availa
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
GlobeNewswire Inc.
Oct 09, 2025 11:04 AM GMT
Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competitionA $5K donation from the Company was split between ILADEF and GLA to recognize the winning nameB-FREE, a Phase 2 trial, will commence in earl
60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 03, 2025 12:02 PM GMT
WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today th